CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 143 enrolled
Drug / intervention
Azacitidine +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01928576
NCT01928576Phase 2Completed
CompareCT.gov

A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Aug 26, 2013·Updated May 3, 2024

In Brief

A Phase 2 clinical trial evaluating Azacitidine, Entinostat, and 2 other interventions for Non-Small Cell Lung Cancer and Epigenetic Therapy. Completed, enrolled 143 participants across 5 sites.

Detailed Summary

Response Rate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Epigenetic Therapy
CountriesUnited States
CollaboratorsRising Tide Foundation, Stand Up To Cancer, Bristol-Myers Squibb, Celgene, Syndax Pharmaceuticals, Rhone-Poulenc Rorer

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 26, 2013
Enrollment StartNov 6, 2013
Primary CompletionApr 4, 2023
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 12.8 years ago

Interventions

Azacitidinedrug

Entinostatdrug

Nivolumabdrug

CC-486 300drug